OsoBio appoints Dr. Paul Stoker Director of Laboratories

Dr. Stoker brings to new role nearly 20 years of experience in pharmaceutical quality control
Albuquerque, NM Feb 21, 2014 – OsoBio has appointed Paul W. Stoker, Ph.D., director of its chemistry and microbiology laboratories.
As part of the company’s quality control department, the laboratories are responsible for testing the in-process and finished products – as well as raw materials and components – involved in OsoBio’s cGMP sterile manufacturing operations. The labs also are charged with environmental monitoring and analytical method development.
“While continuous quality compliance is key to OsoBio’s business success, it’s even more important to the patients who rely upon the medications we manufacture – and we try to never lose sight of that fact,” said Milton Boyer, president of OsoBio. “Paul will lead a team of scientists who are knowledgeable, capable and highly committed to integrity – delivering excellence to both our clients and the patients we collectively serve.”
Stoker fills a position vacated when Kathleen Larese, OsoBio’s previous director of laboratories, became the company’s director of technical operations.
Stoker brings to OsoBio nearly 20 years of professional experience managing pharmaceutical laboratories responsible for quality control. Most recently, he served as director of the quality control laboratory at Dendreon, a company that researches, develops, commercializes and manufactures cancer therapeutics. Prior to that, he directed quality control and analytical laboratories for Nektar Therapeutics, a clinical-stage biopharmaceutical company.
Stoker earned his doctorate in biochemistry from the University of Nebraska. He also holds from Brigham Young University a master’s degree in zoology with an emphasis in toxicology and statistics, as well as a bachelor’s degree in chemistry.
OSO BioPharmaceuticals Manufacturing, LLC, is a contract manufacturing organization (CMO) that specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry. The company offers significant knowledge and experience in late-phase clinical products and successfully taking them to commercialization.
In the history of our Albuquerque, N.M., facility, OsoBio has manufactured more than 250 distinct commercial presentations in every major therapeutic category. The U.S. Drug Enforcement Administration (DEA) has granted OsoBio registrations for Schedule II-V controlled substances.